asked my compounder where the API comes from. long silence.
asked my compounder where the API comes from. long silence. Not a hot take, just something I have not seen said plainly here.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
On concentration, which is where I see people actually get hurt.
A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.
Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
a telehealth intake that asks nothing has told you what it is
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Left up. It describes an arrangement with specifics and it is honest about the jurisdiction.
do not assume the concentration matches the branded product
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
the pharmacy and the prescriber are two separate questions
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
a 503B has to register and report, so there is a paper trail to ask for
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
- 1Left up. It describes an arrangement with specifics and it is honest about…10 comments in this branch · started by u/usp_appendix